Brief: Algernon Submits Investigational New Drug Application For Multinational Phase 2B/3 Human Study To Evaluate Ifenprodil For Covid-19

Grey Matters Health

26/05/2020 13:57

May 26 (Reuters) - Algernon Pharmaceuticals Inc  AGN.CD :
    * ALGERNON SUBMITS INVESTIGATIONAL NEW DRUG (IND)
APPLICATION WITH
U.S. FDA FOR MULTINATIONAL PHASE 2B/3 HUMAN STUDY TO EVALUATE
IFENPRODIL FOR COVID-19
    * ALGERNON - CAUTIONS  CO IS NOT MAKING ANY EXPRESS OR
IMPLIED
CLAIMS IFENPRODIL IS EFFECTIVE TREATMENT FOR COVID-19 VIRUS

Source text for Eikon:  ID:nGNX39Yfsc 
Further company coverage:  AGN.CD 

 ((Reuters.Briefs@thomsonreuters.com;))